Overview

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

Status:
Terminated
Trial end date:
2012-04-16
Target enrollment:
Participant gender:
Summary
The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Ophthalmic Solutions
Tetrahydrozoline